Group VI iPLA2 Polyclonal Antibody

  • Catalog No.：YT2073
  • Applications：WB;ELISA
  • Reactivity：Human;Mouse;Rat
    • Target：
    • Group VI iPLA2
    • Fields：
    • >>Glycerophospholipid metabolism;>>Ether lipid metabolism;>>Arachidonic acid metabolism;>>Linoleic acid metabolism;>>alpha-Linolenic acid metabolism;>>Metabolic pathways;>>Ras signaling pathway;>>Vascular smooth muscle contraction;>>Fc gamma R-mediated phagocytosis;>>Inflammatory mediator regulation of TRP channels
    • Gene Name：
    • PLA2G6
    • Protein Name：
    • 85/88 kDa calcium-independent phospholipase A2
    • Human Gene Id：
    • 8398
    • Human Swiss Prot No：
    • O60733
    • Mouse Swiss Prot No：
    • P97819
    • Immunogen：
    • Synthesized peptide derived from the Internal region of human Group VI iPLA2.
    • Specificity：
    • Group VI iPLA2 Polyclonal Antibody detects endogenous levels of Group VI iPLA2 protein.
    • Formulation：
    • Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
    • Source：
    • Polyclonal, Rabbit,IgG
    • Dilution：
    • WB 1:500 - 1:2000. ELISA: 1:5000. Not yet tested in other applications.
    • Purification：
    • The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
    • Concentration：
    • 1 mg/ml
    • Storage Stability：
    • -15°C to -25°C/1 year(Do not lower than -25°C)
    • Other Name：
    • PLA2G6;PLPLA9;85/88 kDa calcium-independent phospholipase A2;CaI-PLA2;Group VI phospholipase A2;GVI PLA2;Intracellular membrane-associated calcium-independent phospholipase A2 beta;iPLA2-beta;Patatin-like phospholipase domain-contai
    • Observed Band(KD)：
    • 90kD
    • Background：
    • The protein encoded by this gene is an A2 phospholipase, a class of enzyme that catalyzes the release of fatty acids from phospholipids. The encoded protein may play a role in phospholipid remodelling, arachidonic acid release, leukotriene and prostaglandin synthesis, fas-mediated apoptosis, and transmembrane ion flux in glucose-stimulated B-cells. Several transcript variants encoding multiple isoforms have been described, but the full-length nature of only three of them have been determined to date. [provided by RefSeq, Dec 2010],
    • Function：
    • catalytic activity:Phosphatidylcholine + H(2)O = 1-acylglycerophosphocholine + a carboxylate.,disease:Defects in PLA2G6 are a cause of neurodegeneration with brain iron accumulation (NBIA) [MIM:610217]. NBIA comprises a clinically and genetically heterogeneous group of disorders with high basal ganglia iron.,disease:Defects in PLA2G6 are the cause of infantile neuroaxonal dystrophy 1 (INAD1) [MIM:256600]; also known as Seitelberger disease. Infantile neuroaxonal dystrophy (INAD) is a neurodegenerative disease characterized by pathologic axonal swelling and spheroid bodies in the central nervous system. Onset is within the first 2 years of life with death by age 10 years.,disease:Defects in PLA2G6 are the cause of Karak syndrome [MIM:608395]. Karak syndrome is a neurologic disease characterized by early-onset progressive cerebellar ataxia, dystonia, spasticity, intellectual and features c
    • Subcellular Location：
    • Cytoplasm . Cell membrane . Mitochondrion . Cell projection, pseudopodium . Recruited to the membrane-enriched pseudopods upon MCP1/CCL2 stimulation in monocytes. .
    • Expression：
    • Four different transcripts were found to be expressed in a distinct tissue distribution.

    Attributes

    • Code：
    • YT2073
    • Size
    • 40μL / 100μL / 200μL
    • Price$：
    • 150 / 280 / 450
    • Delivery：
    • 2024-11-24
    Order

    Related Products